“ATH434 has the potential to address the underlying pathology of Multiple System Atrophy” - BSA bureau

Melbourne-based biotech company Alterity Therapeutics has just announced the opening of its Phase 2 clinical trial for lead candidate ATH434 for patients with Multiple System Atrophy (MSA)- a rare neurodegenerative disease, similar to Parkinson’s, for which t…

Melbourne-based biotech company Alterity Therapeutics has just announced the opening of its Phase 2 clinical trial for lead candidate ATH434 for patients with Multiple System Atrophy (MSA)- a rare ne… [+4364 chars]

full article...